Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | SSTR2 | P30874 | 2/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.37 |
| ▸ | TTR | P02766 | 2/20 | 0.36 |
| ▸ | CTSD | P07339 | 6/20 | 0.35 |
| ▸ | CTSE | P14091 | 6/20 | 0.35 |
| ▸ | BACE1 | P56817 | 4/20 | 0.35 |
| ▸ | REN | P00797 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20684299 | 1.00 | CYP3A4 (0.43) | CYP3A4SSTR2FOLH1TTRCTSD | |
| SCHEMBL15047596 | 1.00 | CYP3A4 (0.43) | CYP3A4SSTR2FOLH1TTRCTSD | |
| SCHEMBL2734904 | 0.96 | CYP3A4 (0.42) | CYP3A4SSTR2FOLH1TTRCTSD | |
| SCHEMBL19490727 | 0.96 | CYP3A4 (0.42) | CYP3A4SSTR2FOLH1TTRCTSD | |
| SCHEMBL19372571 | 0.96 | CYP3A4 (0.42) | CYP3A4SSTR2FOLH1TTRCTSD | |
| SCHEMBL13034951 | 0.96 | CYP3A4 (0.42) | CYP3A4SSTR2FOLH1TTRCTSD | |
| SCHEMBL22559870 | 0.94 | CYP3A4 (0.43) | CYP3A4SSTR2FOLH1TTRCTSD | |
| SCHEMBL19976520 | 0.94 | CYP3A4 (0.42) | CYP3A4SSTR2FOLH1TTRCTSD | |
| SCHEMBL13838248 | 0.94 | CYP3A4 (0.41) | CYP3A4SSTR2FOLH1TTRCTSD | |
| SCHEMBL3266288 | 0.94 | CYP3A4 (0.41) | CYP3A4SSTR2FOLH1TTRCTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230346968-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | AGENSYS, INC. (US) | 2023-11-02 | — | — | US | disclosed |
| US-10981987-B2 | Humanized anti-CD79b antibodies and immunoconjugates and methods of use | GENENTECH, INC. (US) | 2021-04-20 | — | — | US | disclosed |
| US-20200347149-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | SEAGEN INC. | 2020-11-05 | — | — | US | disclosed |
| US-10246510-B2 | KIR3DL2 binding agents | INNATE PHARMA (FR) | 2019-04-02 | — | — | US | disclosed |
| EP-3434275-A1 | ASSAY FOR CANCER CELLS BASED ON THE USE OF AURISTATIN CONJUGATES WITH ANTIBODIES | Seattle Genetics, Inc. (US) | 2019-01-30 | — | — | EP | disclosed |
| US-20180201679-A1 | HUMANIZED ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | GENENTECH INC (US) | 2018-07-19 | — | — | US | disclosed |
| EP-2621526-B1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | AGENSYS INC (US) | 2018-06-06 | — | — | EP | disclosed |
| US-9896506-B2 | Anti-CD79B antibodies and immunoconjugates and methods of use | GENENTECH, INC. (US) | 2018-02-20 | — | — | US | disclosed |
| US-20170362318-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF TUMOR HEMATOPOIETIC ORIGIN | GENENTECH INC (US) | 2017-12-21 | — | — | US | disclosed |
| US-9845355-B2 | Humanized anti-CD79b antibodies and immunoconjugates and methods of use | GENENTECH, INC. (US) | 2017-12-19 | — | — | US | disclosed |
| WO-2009048967-A1 | COMBINATION THERAPY WITH ANTIBODY-DRUG CONJUGATES | SEATTLE GENETICS, INC. (US) | 2009-04-16 | — | — | WO | disclosed |
| US-20090068202-A1 | Humanized Anti-CD79B Antibodies and Immunoconjugates and Methods of Use | GENENTECH, INC. (US) | 2009-03-12 | — | — | US | disclosed |
| US-7498298-B2 | Auristatin and dolastatin analogs; for treating cancer, autoimmune diseases and infectious diseases | SEATTLE GENETICS, INC. (US) | 2009-03-03 | — | — | US | disclosed |
| US-20090047296-A1 | Antibodies conjugated to Auristatin analogs via a maleimidocaproyl lingages; for treating cancer, autoimmune diseases and infectious diseases | SEATTLE GENETICS, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-20090028856-A1 | Anti-CD79B Antibodies and Immunoconjugates and Methods of Use | GENENTECH, INC. (US) | 2009-01-29 | — | — | US | disclosed |
| WO-2009012256-A1 | HUMANIZED ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | GENENTECH, INC. (US) | 2009-01-22 | — | — | WO | disclosed |
| US-20080248053-A1 | Antibody-drug conjugates; Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF); cancer; autoimmune diseases | SEATTLE GENETICS, INC. (US) | 2008-10-09 | — | — | US | disclosed |
| US-20080248051-A1 | Antibody-drug conjugates; Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF); cancer; autoimmune diseases | SEATTLE GENETICS, INC. (US) | 2008-10-09 | — | — | US | disclosed |
| US-20080241128-A1 | Antibodies; anticancer agents; autoimmune disorders | SEATTLE GENETICS, INC. (US) | 2008-10-02 | — | — | US | disclosed |
| WO-2007140371-A2 | ANTIBODIES AND IMMUNOCONJUGATES AND USES THEREFOR | GENENTECH, INC. (US) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10981987-B2 | Humanized anti-CD79b antibodies and immunoconjugates and methods of use | CD99, CD79B, CD47 | CYP3A4 4811/4885SSTR2 3649/4885FOLH1 544/4885 |
| US-10246510-B2 | KIR3DL2 binding agents | KLRK1, KCNA3, KCNK3 | CYP3A4 2294/4885SSTR2 3601/4885FOLH1 3002/4885 |
| US-20090047296-A1 | Antibodies conjugated to Auristatin analogs via a maleimidocaproyl lingages; for treating cancer, autoimmune diseases and infectious diseases | MMAB, CAD, TRIM59 | CYP3A4 2414/4885SSTR2 2018/4885FOLH1 343/4885 |
| US-20080248053-A1 | Antibody-drug conjugates; Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF); cancer; autoimmune diseases | MMAB, CAD, VIM | CYP3A4 1668/4885SSTR2 2848/4885FOLH1 385/4885 |
| US-20180201679-A1 | HUMANIZED ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | CD99, CD79B, CD47 | CYP3A4 4811/4885SSTR2 3649/4885FOLH1 544/4885 |
| US-20080241128-A1 | Antibodies; anticancer agents; autoimmune disorders | SSB, B3GAT3, CD74 | CYP3A4 1390/4885SSTR2 4207/4885FOLH1 166/4885 |
| US-20080248051-A1 | Antibody-drug conjugates; Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF); cancer; autoimmune diseases | MMAB, CAD, VIM | CYP3A4 1668/4885SSTR2 2848/4885FOLH1 385/4885 |
| US-20090028856-A1 | Anti-CD79B Antibodies and Immunoconjugates and Methods of Use | CD99, CD79B, CD47 | CYP3A4 4871/4885SSTR2 3726/4885FOLH1 1010/4885 |
| US-20090068202-A1 | Humanized Anti-CD79B Antibodies and Immunoconjugates and Methods of Use | CD99, CD79B, CD47 | CYP3A4 4811/4885SSTR2 3649/4885FOLH1 544/4885 |
| US-20170362318-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF TUMOR HEMATOPOIETIC ORIGIN | HCLS1, MCL1, CD47 | CYP3A4 4525/4885SSTR2 4580/4885FOLH1 459/4885 |
| US-20230346968-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | IGSF11, CD2BP2, PA2G4 | CYP3A4 3443/4885SSTR2 4102/4885FOLH1 133/4885 |
| US-20200347149-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | MMAB, CAD, VIM | CYP3A4 1021/4885SSTR2 3233/4885FOLH1 237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.